ERCC1 gene polymorphism in gastric cancer

Abstract

Tian Yuan, Shan Zezhi, Peng Jiayuan, Wang Yu. ERCC1 gene polymorphism in gastric cancer[J]. Journal of International Oncology, 2014, 41(8): 666-668.

［1］ Proserpio I, Rausei S, Barzaghi S, et al. Multimodal treatment of gastric cancer［J］. World J Gastrointest Surg, 2014, 6(4): 55-58. ［2］ Zaanan A, Dalban C, Emile JF, et al. ERCC1, XRCC1 and GSTP1 single nucleotide polymorphisms and survival of patients with colon cancer receiving oxaliplatinbased adjuvant chemotherapy［J］. J Cancer, 2014, 5(6): 425-432. ［3］ Cui S, Jiang L. Current translational tesearch status of ERCC1 expression of nonsmall cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2014, 17(5): 428-432. ［4］ Kirschner K, Melton DW. Multiple roles of the ERCC1XPF endonuclease in DNA repair and resistance to anticancer drugs［J］. Anticancer Res, 2010, 30(9): 3223-3232. ［5］ Yin M, Yan J, Martinez BE, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatinbased chemotherapies in gastric and colorectal cancer: a systemic review and metaanalysis［J］. Clin Cancer Res, 2011, 17(6): 1632-1640. ［6］ Squires MH, Fisher SB, Fisher KE, et al. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma［J］. Cancer, 2013, 119(17): 3242-3250. ［7］ Wang J, Zhou XQ, Li JY, et al. Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer［J］. Chin J Cancer Res, 2014, 26(3): 323-330. ［8］ Yamada Y, Boku N, Nishina T, et al. Impact of excision repair crosscomplementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912［J］. Ann Oncol, 2013, 24(10): 2560-2565. ［9］周倩茹, 邱红, 胡广原, 等. ERCC1和FGFR2在胃癌组织中的表达及其临床意义［J］. 肿瘤防治研究, 2012, 39(11): 1344-1348. ［10］ Doecke J, Zhao ZZ, Pandeya N, et al. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma［J］. Int J Cancer, 2008, 123(1): 174-180. ［11］ Hou R, Liu Y, Feng Y, et al. Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use［J］. Gene, 2014, 548(1): 1-5. ［12］ Li HY, Ge X, Huang GM, et al. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatinbased adjuvant chemotherapy in colorectal cancer in Chinese population［J］. Asian Pac J Cancer Prev, 2012, 13(7): 3465-3469. ［13］ Mazzoni F, Cecere FL, Meoni G, et al. Phase Ⅱ trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced nonsmallcell lung cancer［J］. Lung Cancer, 2013, 82(2): 288-293. ［14］ Sakano S, Ogawa S, Yamamoto Y, et al. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy［J］. Mol Clin Oncol, 2013, 1(3): 403-410. ［15］李师怡, 陈刚, 林贤东, 等. ERCC1基因多态性与胃癌发生发展的关系［J］. 中国肿瘤临床, 2012, 39(13): 907-910. ［16］ Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, openlabel phase 3 trial［J］. Lancet Oncol, 2013, 14(6): 490-499. ［17］ Lo Nigro C, Monteverde M, Riba M, et al. Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer［J］. Int J Oncol, 2010, 37(5): 1219-1228. ［18］ Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S1 plus cisplatin in metastatic gastric cancer patients［J］. Br J Cancer, 2011, 104(7): 1126-1134. ［19］ Rumiato E, Cavallin F, Boldrin E, et al. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5FUbased neoadjuvant therapy［J］. Pharmacogenet Genomics, 2013, 23(11): 597-604. ［20］ Li J, Zuo X, Lv X, et al. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population［J］. Tumour Biol, 2014, 35(8): 7569-7574.

[1]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492.
[6]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185.
[9]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116.
[10]	Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86.
[11]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.
[12]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682.
[13]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635.
[14]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281.
[15]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun.Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer[J]. Journal of International Oncology, 2022, 49(12): 724-728.

ERCC1 gene polymorphism in gastric cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments